Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DANISCO PROBIOTIC is a brand name for a probiotic supplement. One product marketed under this name is manufactured by Vgas Pharmaceutical Joint Stock Company and contains spores of *Bacillus clausii* and *Bacillus subtilis*. [1] It is formulated as an oral liquid and is indicated for the treatment and prevention of intestinal microflora disorders, such as those caused by antibiotic use, leading to symptoms like diarrhea, constipation, and indigestion. [1] It is classified as a functional food or dietary supplement. The developer, Danisco (now part of DuPont Nutrition & Biosciences), has also sponsored clinical research on other probiotic strains for different indications, such as a Phase 2 trial assessing *Lactobacillus paracasei* Lpc-37 (also called Lacticaseibacillus paracasei Lpc-37) for modulating psychological stress. [2, 3, 4, 5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DANISCO PROBIOTIC.